Company profile for Novimmune SA

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Novimmune SA is a privately held, Swiss biopharmaceutical company. Novimmune has been granted Breakthrough therapy designation for emapalumab by the US Food and Drug Administration (FDA) and was also selected for PRIME (PRIority MEdicine) by the European Medicines Agency (EMA). Novimmune has signed two exclusive partnering agreements with Genentech, a member of the Roche Group: in 2010 on an anti-IL17 and in 2016 on an anti-TL...
Novimmune SA is a privately held, Swiss biopharmaceutical company. Novimmune has been granted Breakthrough therapy designation for emapalumab by the US Food and Drug Administration (FDA) and was also selected for PRIME (PRIority MEdicine) by the European Medicines Agency (EMA). Novimmune has signed two exclusive partnering agreements with Genentech, a member of the Roche Group: in 2010 on an anti-IL17 and in 2016 on an anti-TLR4 monoclonal antibody. Novimmune is currently performing a phase 2 study in Rheumatoid Arthritis, with this latter molecule, with results expected in the third quarter 2018.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Switzerland
Address
Address
14 Chemin des Aulx 1228 Plan-Les-Ouates Geneva – Switzerland
Telephone
Telephone
+41 22 839 71 41
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761107

FDA
27 Jun 2025

https://endpts.com/sobi-bets-250m-cash-more-than-1b-in-milestones-for-rights-to-a-c3-therapy-being-pushed-through-5-pivotal-trials/

N.DeFeudis ENDPTS
28 Oct 2020

https://www.fiercebiotech.com/biotech/novimmune-unit-nabs-takeda-milestone-payment-for-hemophilia-work

Ben Adams FIERCE BIOTECH
14 Feb 2020

https://in.reuters.com/article/us-sobi-aquisition/sobi-buys-rare-disease-drug-emapalumab-zooms-in-on-hematology-and-immunology-idINKCN1TD1MZ

REUTERS
13 Jun 2019
Sobi to buy Novimmune R&D assets, lay off 90 staff
Sobi to buy Novimmune R&D assets, lay off 90 staff

12 Jun 2019

// Nick P. Taylor FIERCE BIOTECH

https://www.fiercebiotech.com/biotech/sobi-to-buy-novimmune-r-d-assets-lay-off-90-staff

Nick P. Taylor FIERCE BIOTECH
12 Jun 2019

https://www.prnewswire.com/news-releases/sobi-acquires-emapalumab-and-related-assets-300866267.html

PR NEWSWIRE
12 Jun 2019

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty